This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Quirt, I. Articles by Couture, F. Search for Related Content PubMed PubMed Citation Articles by Quirt, I. Articles by Couture, F. Social Bookmarking                            What's this?

Epoetin Alfa Therapy Increases Hemoglobin Levels and Improves Quality of Life in Patients With Cancer-Related Anemia Who Are Not Receiving Chemotherapy and Patients With Anemia Who Are Receiving Chemotherapy

From the Princess Margaret Hospital; Janssen-Ortho Inc, Toronto; and London Regional Cancer Centre, London, Ontario; Royal Victoria Hospital, Montreal; Hôtel-Dieu de Lévis, Lévis; Hôtel-Dieu de Québec, Québec City, Québec; St John Regional Hospital Facility, St John, New Brunswick; Dr H Bliss Murphy Cancer Center, St John’s, Newfoundland; and British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

Address reprint requests to Ian Quirt, MD, Princess Margaret Hospital, Department of Medical Oncology and Hematology, 610 University Ave, Toronto, Ontario, Canada M5G 2M9; email: ian.quirt{at}uhn.on.ca

PURPOSE: To evaluate efficacy, safety, and quality of life (QOL) changes with epoetin alfa therapy for anemia in patients with nonmyeloid malignancies.

PATIENTS AND METHODS: Anemic cancer patients were enrolled onto this prospective, open-label study from 34 centers across Canada. The trial had two cohorts: patients who were and were not receiving chemotherapy during the 16-week study. All patients initially received epoetin alfa 150 IU/kg subcutaneously three times per week. The dose was doubled after 4 weeks for patients who did not experience sufficient response.

RESULTS: Of the 183 patients enrolled in the nonchemotherapy cohort, statistically significant and clinically relevant improvements in QOL were observed with epoetin alfa therapy using both the FACT-An questionnaire and linear analog scale assessment. Hemoglobin levels increased significantly (P < .001; mean increase 2.5 g/dL from baseline to end of study) and these increases were positively correlated with improved QOL and change in Eastern Cooperative Oncology Group (ECOG) scores. There was a significant reduction in the percentage of patients who required blood transfusions. The 218 patients in the chemotherapy cohort also experienced significant improvements in QOL, decreased transfusion use, and increased hemoglobin levels that correlated with QOL improvements and change in ECOG scores. Epoetin alfa was well-tolerated in both cohorts.

CONCLUSION: Epoetin alfa administered to patients with cancer-related anemia for up to 16 weeks resulted in significantly improved QOL, increased hemoglobin levels, and decreased transfusion use. These benefits were observed in cancer patients who were not receiving chemotherapy as well as those who were.

All trademark rights used under license. Eprex is also marketed as Procrit (Ortho Biotech Inc, Raritan, NJ).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Gordon, G. Nichols, A. Ben-Jacob, D. Tomita, T. Lillie, and C. Miller Treating Anemia of Cancer with Every-4-Week Darbepoetin Alfa: Final Efficacy and Safety Results from a Phase II, Randomized, Double-Blind, Placebo-Controlled Study Oncologist, June 1, 2008; 13(6): 715 - 724. [Abstract] [Full Text] [PDF]

				R. E. Smith Jr, M. S. Aapro, H. Ludwig, T. Pinter, M. Smakal, T. E. Ciuleanu, L. Chen, T. Lillie, and J. A. Glaspy Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study J. Clin. Oncol., March 1, 2008; 26(7): 1040 - 1050. [Abstract] [Full Text] [PDF]

				A. G. Shankar The Role of Recombinant Erythropoietin in Childhood Cancer Oncologist, February 1, 2008; 13(2): 157 - 166. [Abstract] [Full Text] [PDF]

				V. Charu, C. P. Belani, A. N. Gill, M. Bhatt, D. Tomita, G. Rossi, and A. Ben-Jacob Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial Oncologist, June 1, 2007; 12(6): 727 - 737. [Abstract] [Full Text] [PDF]

				P. Cremieux, F. Vekeman, and P. Lefebvre Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 165 - 178. [Abstract] [PDF]

				I. Quirt, M. Kovacs, F. Couture, A. R. Turner, M. Noble, R. Burkes, S. Dolan, R. K. Plante, C. Y. Lau, J. Chang, et al. Patients Previously Transfused or Treated with Epoetin Alfa at Low Baseline Hemoglobin Are at Higher Risk for Subsequent Transfusion: An Integrated Analysis of the Canadian Experience Oncologist, January 1, 2006; 11(1): 73 - 82. [Abstract] [Full Text] [PDF]

				E. J. Kruep and L. E. Basskin Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting Am. J. Health Syst. Pharm., December 15, 2005; 62(24): 2597 - 2603. [Abstract] [Full Text] [PDF]

				R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns Oncologist, August 1, 2005; 10(7): 539 - 554. [Abstract] [Full Text] [PDF]

				T. E. Witzig, P. T. Silberstein, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, J. A. Mailliard, K. M. Rowland, S. R. Alberts, J. E. Krook, R. Levitt, et al. Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy J. Clin. Oncol., April 20, 2005; 23(12): 2606 - 2617. [Abstract] [Full Text] [PDF]

				F. Couture, A.R. Turner, B. Melosky, L. Xiu, R.K. Plante, C.Y. Lau, and I. Quirt Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin Management Oncologist, January 1, 2005; 10(1): 63 - 71. [Abstract] [Full Text] [PDF]

				E. Lindholm, P. Daneryd, U. Korner, A. Hyltander, M. Fouladiun, and K. Lundholm Effects of Recombinant Erythropoietin in Palliative Treatment of Unselected Cancer Patients Clin. Cancer Res., October 15, 2004; 10(20): 6855 - 6864. [Abstract] [Full Text] [PDF]

				M. Auerbach, H. Ballard, J. R. Trout, M. McIlwain, A. Ackerman, H. Bahrain, S. Balan, L. Barker, and J. Rana Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial J. Clin. Oncol., April 1, 2004; 22(7): 1301 - 1307. [Abstract] [Full Text] [PDF]

				Epoetins and {blacktriangledown}darbepoetin alfa in malignant disease DTB, March 1, 2004; 42(3): 21 - 24. [Abstract] [Full Text] [PDF]

				J. M Kolesar, B. A Duren, and B. G Baranski Retrospective evaluation of response to epoetin alfa in patients with hematologic disorders Journal of Oncology Pharmacy Practice, March 1, 2004; 10(1): 1 - 6. [Abstract] [PDF]

				D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine Arch Intern Med, February 9, 2004; 164(3): 262 - 276. [Abstract] [Full Text] [PDF]

				D. H. Henry The Evolving Role of Epoetin Alfa in Cancer Therapy Oncologist, February 1, 2004; 9(1): 97 - 107. [Abstract] [Full Text] [PDF]

				M. J. Weiss New Insights Into Erythropoietin and Epoetin Alfa: Mechanisms of Action, Target Tissues, and Clinical Applications Oncologist, December 1, 2003; 8(90003): 18 - 29. [Abstract] [Full Text] [PDF]

				B. Kralj, D. Iverson, K. Hotz, and F. D. Ashbury The Impact of Computerized Clinical Reminders on Physician Prescribing Behavior: Evidence From Community Oncology Practice American Journal of Medical Quality, September 1, 2003; 18(5): 197 - 203. [Abstract] [PDF]

				D. Cella, D. Dobrez, and J. Glaspy Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes Ann. Onc., April 1, 2003; 14(4): 511 - 519. [Abstract] [Full Text] [PDF]